Pub Date : 2025-02-06DOI: 10.3324/haematol.2025.287356
Maria I Zervou, George N Goulielmos
Not available.
{"title":"Comment on: Multimorbidity, comorbidity, frailty, and venous thromboembolism.","authors":"Maria I Zervou, George N Goulielmos","doi":"10.3324/haematol.2025.287356","DOIUrl":"https://doi.org/10.3324/haematol.2025.287356","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-06DOI: 10.3324/haematol.2025.287469
Bengt Zöller, Jean M Connors
Not available.
{"title":"Response to Comment on: Multimorbidity, comorbidity, frailty, and venous thromboembolism.","authors":"Bengt Zöller, Jean M Connors","doi":"10.3324/haematol.2025.287469","DOIUrl":"https://doi.org/10.3324/haematol.2025.287469","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-06DOI: 10.3324/haematol.2024.285343
Adrian G Minson, Michael J Dickinson
The CD20xCD3 T-cell-engaging bispecific antibodies are a highly active new treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Epcoritamab and glofitamab have both been approved in over thirty countries as monotherapy for DLBCL after two prior treatment lines; odronextamab has recent European approval, and mosunetuzumab is active and is being developed as a combination partner. These agents can be safely combined with other immunotherapies and chemotherapy, and single-arm and randomised trial outcomes promise an expanding role for this class of drugs in earlier treatment lines. This review examines the clinical development of the CD20xCD3 bispecific antibodies in DLBCL, how the phase I and II trials inform their current use, and the key distinctions between the agents. We focus on the efficacy and safety of those bispecific antibodies most advanced in development. We also consider emerging understandings of resistance mechanisms. Finally, we review key ongoing trials and combinations and consider the potential future of bispecific antibodies within the sequence of available treatments for DLBCL.
{"title":"New bispecific antibodies in diffuse large B-cell lymphoma.","authors":"Adrian G Minson, Michael J Dickinson","doi":"10.3324/haematol.2024.285343","DOIUrl":"https://doi.org/10.3324/haematol.2024.285343","url":null,"abstract":"<p><p>The CD20xCD3 T-cell-engaging bispecific antibodies are a highly active new treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Epcoritamab and glofitamab have both been approved in over thirty countries as monotherapy for DLBCL after two prior treatment lines; odronextamab has recent European approval, and mosunetuzumab is active and is being developed as a combination partner. These agents can be safely combined with other immunotherapies and chemotherapy, and single-arm and randomised trial outcomes promise an expanding role for this class of drugs in earlier treatment lines. This review examines the clinical development of the CD20xCD3 bispecific antibodies in DLBCL, how the phase I and II trials inform their current use, and the key distinctions between the agents. We focus on the efficacy and safety of those bispecific antibodies most advanced in development. We also consider emerging understandings of resistance mechanisms. Finally, we review key ongoing trials and combinations and consider the potential future of bispecific antibodies within the sequence of available treatments for DLBCL.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-06DOI: 10.3324/haematol.2024.286111
Aida Zeckanovic, Brice Mouttet, Luciana Vinti, Philip Ancliff, Benoît Brethon, Gunnar Cario, Sarah Elitzur, Volkan Hazar, Joachim Kunz, Anja Möricke, Jerry Stein, Yöntem Yaman, Jochen Buechner, Magnus Aasved Hjort, David O'Connor, Angus Hodder, Jack Bartram, Julia Alten, Draga Barbaric, Gabriele Escherich, Nicolas Boissel, Loïc Vasseur, Emmanuelle Clappier, Laure Farnault, Sarah Bonnet, Katharine Patrick, Martin Schrappe, Sema Anak, André Baruchel, Franco Locatelli, Martin Stanulla, Arend Von Stackelberg, Nicole Bodmer, Jean-Pierre Bourquin
Not available.
{"title":"Update on long-term outcomes of a cohort of patients with TCF3::HLF positive acute lymphoblastic leukemia treated with blinatumomab and stem cell transplantation.","authors":"Aida Zeckanovic, Brice Mouttet, Luciana Vinti, Philip Ancliff, Benoît Brethon, Gunnar Cario, Sarah Elitzur, Volkan Hazar, Joachim Kunz, Anja Möricke, Jerry Stein, Yöntem Yaman, Jochen Buechner, Magnus Aasved Hjort, David O'Connor, Angus Hodder, Jack Bartram, Julia Alten, Draga Barbaric, Gabriele Escherich, Nicolas Boissel, Loïc Vasseur, Emmanuelle Clappier, Laure Farnault, Sarah Bonnet, Katharine Patrick, Martin Schrappe, Sema Anak, André Baruchel, Franco Locatelli, Martin Stanulla, Arend Von Stackelberg, Nicole Bodmer, Jean-Pierre Bourquin","doi":"10.3324/haematol.2024.286111","DOIUrl":"https://doi.org/10.3324/haematol.2024.286111","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-06DOI: 10.3324/haematol.2024.286973
Eva N Hamulyák, Tzu-Fei Wang, Lisa Baumann Kreuziger, Varun Iyengar, Brian J Carney, Ann Hoeben, Berna C Özdemir, Rosana D Cordova Serrano, Kristen M Sanfilippo, Shira Rozenblatt, Ludo F M Beenen, Shlomit Yust-Katz, Erez Halperin, Ariela Arad, Aharon Lubetsky, Marc Carrier, Benjamin Massat, Harry R Büller, Galia Spectre, Jeffrey I Zwicker, Avi Leader
Not available.
{"title":"Multinational cohort study of intracranial hemorrhage in patients with brain metastases receiving anticoagulation.","authors":"Eva N Hamulyák, Tzu-Fei Wang, Lisa Baumann Kreuziger, Varun Iyengar, Brian J Carney, Ann Hoeben, Berna C Özdemir, Rosana D Cordova Serrano, Kristen M Sanfilippo, Shira Rozenblatt, Ludo F M Beenen, Shlomit Yust-Katz, Erez Halperin, Ariela Arad, Aharon Lubetsky, Marc Carrier, Benjamin Massat, Harry R Büller, Galia Spectre, Jeffrey I Zwicker, Avi Leader","doi":"10.3324/haematol.2024.286973","DOIUrl":"https://doi.org/10.3324/haematol.2024.286973","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-06DOI: 10.3324/haematol.2024.286675
Matthew Ho, Luca Paruzzo, Janna Minehart, Teja Voruganti, Pooja Devi, Dan T Vogl, Adam D Cohen, Alfred L Garfall, Adam J Waxman, Shivani Kapur, Edward A Stadtmauer, Sandra Susanibar Adaniya, Sarah Longworth
Not available.
{"title":"Nontuberculous mycobacterial infections following teclistamab in multiple myeloma.","authors":"Matthew Ho, Luca Paruzzo, Janna Minehart, Teja Voruganti, Pooja Devi, Dan T Vogl, Adam D Cohen, Alfred L Garfall, Adam J Waxman, Shivani Kapur, Edward A Stadtmauer, Sandra Susanibar Adaniya, Sarah Longworth","doi":"10.3324/haematol.2024.286675","DOIUrl":"10.3324/haematol.2024.286675","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-06DOI: 10.3324/haematol.2024.286695
Matthew Schwede, Gladys Rodriguez, Vanessa E Kennedy, Solomon Henry, Douglas Wood, Gabriel N Mannis, Ravindra Majeti, Jonathan H Chen, Eran Bendavid, Tian Yi Zhang
Not available.
{"title":"The improved prognosis of <i>FLT3</i>-internal tandem duplication but not tyrosine kinase domain mutations in acute myeloid leukemia in the era of targeted therapy: a real-world study using large-scale electronic health record data.","authors":"Matthew Schwede, Gladys Rodriguez, Vanessa E Kennedy, Solomon Henry, Douglas Wood, Gabriel N Mannis, Ravindra Majeti, Jonathan H Chen, Eran Bendavid, Tian Yi Zhang","doi":"10.3324/haematol.2024.286695","DOIUrl":"https://doi.org/10.3324/haematol.2024.286695","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-06DOI: 10.3324/haematol.2024.287056
Kerstin B Kaufmann, Stephanie Z Xie
Not available.
{"title":"Context and timing matters in acute myeloid leukemia: females are the superior hosts.","authors":"Kerstin B Kaufmann, Stephanie Z Xie","doi":"10.3324/haematol.2024.287056","DOIUrl":"https://doi.org/10.3324/haematol.2024.287056","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.3324/haematol.2024.285985
Sabine Kayser, Khaled Sanber, Giovanni Marconi, Agnese Mattei, Marlise R Luskin, Amar Kelkar, Marco Cerrano, Daniel Tuyet Kristensen, Anne Stidsholt Roug, Chiara Sartor, Fabio Giglio, Marta Riva, Lorenzo Rizzo, Francesco Saraceni, Selene Guerzoni, Federica Lessi, Erika Borlenghi, Mark J Levis, Richard F Schlenk, Tania Jain, Cristina Papayannidis
We evaluated response to venetoclax/hypomethylating agents (HMA) in 46 patients with acute myeloid leukemia (AML) characterized by extramedullary disease. The median age of these patients was 65 years (range, 19-81). The patients had a median of two sites of extramedullary disease (range, 1-5) and 35 (76%) had concurrent bone marrow involvement. Twenty (43%) patients had high-risk genetic features according to the European LeukemiaNet 2022 classification. Twenty-nine (63%) had relapsed or were refractory after intensive chemotherapy, including 13 (28%) who had undergone prior allogeneic hematopoietic cell transplantation. Patients received a median of two cycles of venetoclax/HMA (range, 1-31). Twenty (43%) patients achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi) after venetoclax/HMA and five (11%) achieved a partial remission (PR). Six patients were subsequently consolidated with allogeneic hematopoietic cell transplantation (CR/CRi, N=4; PR, N=2). The median follow-up was 49.1 months (95% confidence interval [95% CI]: 26.1 months - not reached) and the median overall survival was 6.4 months (95% CI: 5.1-11 months). One-year and 2-year overall survival rates were 29.3% (95% CI: 18.6-46.2%) and 12.3% (95% CI: 5.5-27.6%), respectively. Age, with a cutoff of 60 years, did not have an impact on overall survival (P=0.90). Relapse occurred in 12 of 20 (60%) patients who achieved CR/CRi after venetoclax/ HMA treatment. Of those, all except one succumbed to their disease. Six (30%) patients were in CR/CRi at last follow-up and two (10%) died in CR. In our cohort of patients with AML with extramedullary disease with high-risk features, treatment with venetoclax/HMA resulted in an encouraging overall response rate of 54% with a CR/CRi rate of 43.5%. However, venetoclax/ HMA alone may not be effective in maintaining disease control.
{"title":"Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax/ hypomethylating agents.","authors":"Sabine Kayser, Khaled Sanber, Giovanni Marconi, Agnese Mattei, Marlise R Luskin, Amar Kelkar, Marco Cerrano, Daniel Tuyet Kristensen, Anne Stidsholt Roug, Chiara Sartor, Fabio Giglio, Marta Riva, Lorenzo Rizzo, Francesco Saraceni, Selene Guerzoni, Federica Lessi, Erika Borlenghi, Mark J Levis, Richard F Schlenk, Tania Jain, Cristina Papayannidis","doi":"10.3324/haematol.2024.285985","DOIUrl":"10.3324/haematol.2024.285985","url":null,"abstract":"<p><p>We evaluated response to venetoclax/hypomethylating agents (HMA) in 46 patients with acute myeloid leukemia (AML) characterized by extramedullary disease. The median age of these patients was 65 years (range, 19-81). The patients had a median of two sites of extramedullary disease (range, 1-5) and 35 (76%) had concurrent bone marrow involvement. Twenty (43%) patients had high-risk genetic features according to the European LeukemiaNet 2022 classification. Twenty-nine (63%) had relapsed or were refractory after intensive chemotherapy, including 13 (28%) who had undergone prior allogeneic hematopoietic cell transplantation. Patients received a median of two cycles of venetoclax/HMA (range, 1-31). Twenty (43%) patients achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi) after venetoclax/HMA and five (11%) achieved a partial remission (PR). Six patients were subsequently consolidated with allogeneic hematopoietic cell transplantation (CR/CRi, N=4; PR, N=2). The median follow-up was 49.1 months (95% confidence interval [95% CI]: 26.1 months - not reached) and the median overall survival was 6.4 months (95% CI: 5.1-11 months). One-year and 2-year overall survival rates were 29.3% (95% CI: 18.6-46.2%) and 12.3% (95% CI: 5.5-27.6%), respectively. Age, with a cutoff of 60 years, did not have an impact on overall survival (P=0.90). Relapse occurred in 12 of 20 (60%) patients who achieved CR/CRi after venetoclax/ HMA treatment. Of those, all except one succumbed to their disease. Six (30%) patients were in CR/CRi at last follow-up and two (10%) died in CR. In our cohort of patients with AML with extramedullary disease with high-risk features, treatment with venetoclax/HMA resulted in an encouraging overall response rate of 54% with a CR/CRi rate of 43.5%. However, venetoclax/ HMA alone may not be effective in maintaining disease control.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"378-384"},"PeriodicalIF":8.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：